| Literature DB >> 32751522 |
Héctor Vázquez-Lorente1, Lourdes Herrera-Quintana1, Jorge Molina-López2, Yenifer Gamarra-Morales1, Beatriz López-González1, Claudia Miralles-Adell1, Elena Planells1.
Abstract
Menopause is a stage of hormonal imbalance in women which, in addition to other physiopathological consequences, poses a risk of deficiency of key micronutrients such as magnesium and vitamin D. A study was made of the influence of a magnesium intervention upon vitamin D status in a postmenopausal population from the province of Granada (Spain). Fifty-two healthy postmenopausal women between 44-76 years of age were included. Two randomized groups-placebo and magnesium (500 mg/day)-were treated during eight weeks. Nutrient intake was assessed using questionnaires based on 72-h recall. Vitamin D was analyzed by liquid chromatography-tandem mass spectrometry. Baseline vitamin D proved deficient in over 80% of the subjects. The administration of magnesium resulted in significantly increased vitamin D levels in the intervention group versus the controls (p < 0.05). Magnesium supplementation improved vitamin D status in the studied postmenopausal women.Entities:
Keywords: liquid chromatography—tandem mass spectrometry; magnesium; post-menopause; vitamin D
Mesh:
Substances:
Year: 2020 PMID: 32751522 PMCID: PMC7468838 DOI: 10.3390/nu12082283
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Study design. MG = Magnesium Group. PG = Placebo Group.
Figure 2Flowchart of participants recruited, enrolled and involved in the clinical study.
General characteristics of the study population by group.
| Features | Reference Values | PG ( | MG ( | |||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Follow-Up | Baseline | Follow-Up | |||||
| Age (Years) | - | 59.7 ± 9.15 | 59.7 ± 9.15 | 57.7 ± 7.58 | 57.7 ± 7.58 | - | - | - |
| Weight (Kg) | - | 69.1 ± 11.0 | 67.8 ± 11.2 | 69.3 ± 14.2 | 69.7 ± 13.6 | 0.23 | 0.43 | 0.62 |
| Height (cm) | - | 157.2 ± 6.01 | 157.2 ± 6.01 | 160.2 ± 6.11 | 160.2 ± 6.11 | - | - | - |
| BMI (Kg/m2) | 22.0–27.0 | 28.0 ± 4.30 | 27.7 ± 4.41 | 26.9 ± 4.88 | 27.7 ± 4.41 | 0.21 | 0.49 | 0.65 |
| Blood pressure | ||||||||
| Normal blood pressure | - | 10 (40) | - | 14 (51) | - | - | - | - |
| High blood pressure | - | 15 (60) | - | 13 (49) | - | - | - | - |
| Physical exercise | ||||||||
| Sedentary | - | 9 (36) | - | 6 (23) | - | - | - | - |
| Non-sedentary | - | 16 (64) | - | 21 (77) | - | - | - | - |
| Smoking habit | ||||||||
| Non-smoker | - | 18 (75) | - | 23 (82) | - | - | - | - |
| Smoker | - | 6 (25) | - | 5 (18) | - | - | - | - |
| Educational level | ||||||||
| Basic educational level | - | 10 (40) | - | 11 (40) | - | - | - | - |
| Secondary or high educational level | - | 15 (60) | - | 16 (60) | - | - | - | - |
| Energy intake (Kcal) | 2000.0 | 1339.5 ± 283.1 | 1232.9 ± 285.5 | 1307.1 ± 323.3 | 1323.4 ± 264.5 | 0.17 | 0.66 | 0.27 |
| CHO intake (g/day) | 275.0 | 146.6 ± 40.3 | 146.5 ± 33.4 | 149.5 ± 48.2 | 150.5 ± 48.5 | 0.84 | 0.89 | 0.75 |
| Protein intake (g/day) | 50.0 | 59.7 ± 14.2 | 57.1 ± 10.4 | 61.1 ± 17.6 | 63.4 ± 15.6 | 0.47 | 0.42 | 0.12 |
| Fat intake (g/day) | 70.0 | 56.1 ± 17.2 | 47.9 ± 18.5 | 53.2 ± 14.7 | 51.8 ± 12.7 | 0.15 | 0.66 | 0.41 |
| Cholesterol intake (mg/day) | <300.0 | 150.6 ± 61.6 | 151.7 ± 64.4 | 154.1 ± 64.6 | 158.3 ± 76.8 | 0.87 | 0.81 | 0.75 |
| Fiber intake (g/day) | >25.0 | 17.1 ± 10.6 | 16.2 ± 4.07 | 15.7 ± 7.72 | 16.5 ± 7.50 | 0.42 | 0.53 | 0.88 |
| P intake (mg/day) | 800.0 | 996.1 ± 257.7 | 993.9 ± 219.1 | 1002.6 ± 318.9 | 1038.8 ± 282.5 | 0.86 | 0.57 | 0.55 |
| Ca intake (mg/day) | 800.0–1000.0 | 728.2 ± 223.1 | 679.9 ± 168.6 | 873.5 ± 250.2 | 832.5 ± 210.6 | 0.69 | 0.56 | 0.01 |
| Mg intake (mg/day) | 320.0 | 237.4 ± 87.0 | 232.7 ± 55.8 | 219.3 ± 71.1 | 726.4 ± 59.9 | 0.99 | 0.001 | 0.001 |
| Vitamin D intake (µg/day) | 10.0 | 3.36 ± 3.00 | 4.34 ± 2.91 | 3.89 ± 3.62 | 3.62 ± 2.57 | 0.35 | 0.72 | 0.57 |
n = 52. BMI = Body Mass Index. CHO = Carbohydrates. P = Phosphorous. Ca = Calcium. Mg = Magnesium. Baseline and follow-up values are expressed as mean ± standard deviation. Both for intra-group and inter-groups p-value, paired and unpaired t-student test was used. Categorial variables are expressed as continuous as sample size (n) and percentage of subjects (%), and chi-square test was used. PG = Placebo Group. MG = Magnesium Group.
Biochemical parameters of the study population by group.
| Features | Reference Values | PG ( | MG ( | |||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Follow-Up | Baseline | Follow-Up | |||||
| Glucose (mg/dL) | 70.0–110.0 | 96.0 ± 19.8 | 95.8 ± 19.9 | 90.1 ± 11.1 | 95.8 ± 18.9 | 0.63 | 0.25 | 0.047 |
| Transferrin (mg/dL) | 200.0–360.0 | 285.9 ± 39.7 | 272.8 ± 43.4 | 284.2 ± 47.7 | 272.8 ± 43.4 | 0.89 | 0.18 | 0.71 |
| Prealbumin (mg/dL) | 20.0–40.0 | 26.6 ± 5.03 | 24.7 ± 5.01 | 24.8 ± 6.45 | 24.7 ± 5.01 | 0.001 | 0.06 | 0.62 |
| Albumin (mg/dL) | 3.50–5.20 | 4.50 ± 0.20 | 4.45 ± 0.27 | 4.50 ± 0.21 | 4.45 ± 0.27 | 0.62 | 0.055 | 0.57 |
| Homocysteine (µmol/L) | <13.0 | 12.5 ± 6.45 | 12.7 ± 4.78 | 11.5 ± 4.25 | 12.7 ± 4.78 | 0.27 | 0.66 | 0.46 |
| Creatinine (mg/dl) | 0.50–0.90 | 0.75 ± 0.16 | 0.75 ± 0.16 | 0.68 ± 0.11 | 0.75 ± 0.16 | 0.31 | 0.81 | 0.08 |
| Total bilirubin (mg/dL) | 0.10–1.20 | 0.49 ± 0.13 | 0.55 ± 0.21 | 0.47 ± 0.11 | 0.55 ± 0.21 | 0.13 | 0.95 | 0.26 |
| LDH (U/L) | 110.0–295.0 | 182.8 ± 29.3 | 181.1 ± 26.1 | 192.5 ± 26.7 | 181.1 ± 26.1 | 0.96 | 0.41 | 0.81 |
| Urea (mg/dL) | 10.0–50.0 | 36.2 ± 10.2 | 36.7 ± 9.35 | 34.3 ± 8.98 | 36.7 ± 9.35 | 0.87 | 0.65 | 0.44 |
| Uric acid (mg/dL) | 2.40–5.70 | 4.51 ± 0.98 | 4.70 ± 1.02 | 4.43 ± 1.23 | 4.70 ± 1.02 | 0.21 | 0.26 | 0.21 |
| Triglycerides (mg/dL) | 50.0–200.0 | 115.8 ± 68.9 | 112.3 ± 62.2 | 111.1 ± 50.6 | 112.3 ± 62.2 | 0.79 | 0.41 | 0.80 |
| HDL (mg/dL) | 40.0–60.0 | 62.6 ± 11.2 | 64.1 ± 12.3 | 66.6 ± 14.4 | 64.1 ± 12.3 | 0.04 | 0.06 | 0.95 |
| LDL (mg/dL) | 70.0–190.0 | 134.5 ± 35.3 | 137.6 ± 30.5 | 130.4 ± 26.4 | 137.6 ± 30.5 | 0.76 | 0.06 | 0.19 |
| Total cholesterol (mg/dL) | 110.0–200.0 | 224.1 ± 39.7 | 221.4 ± 31.4 | 224.7 ± 30.1 | 221.4 ± 31.4 | 0.86 | 0.09 | 0.64 |
| Osteocalcin (ng/mL) | 15.0–46.0 | 17.4 ± 9.45 | 18.1 ± 7.21 | 16.8 ± 10.4 | 18.1 ± 7.21 | 0.69 | 0.22 | 0.91 |
| PTH (pg/mL) | 20.0–70.0 | 50.7 ± 15.8 | 53.3 ± 34.4 | 52.9 ± 17.2 | 53.3 ± 34.4 | 0.46 | 0.07 | 0.29 |
| Ca (mg/dL) | 8.60–10.2 | 9.31 ± 0.31 | 9.14 ± 0.44 | 9.27 ± 0.51 | 9.13 ± 0.49 | 0.31 | 0.07 | 0.98 |
| P (mg/dL) | 2.70–4.50 | 3.45 ± 0.45 | 3.57 ± 0.55 | 3.42 ± 0.53 | 3.60 ± 0.49 | 0.49 | 0.07 | 0.88 |
| 25–OH–D LC–MS/MS (ng/mL) | 30.0–100.0 | 23.0 ± 8.99 | 24.2 ± 7.71 | 23.6 ± 5.70 | 27.8 ± 7.56 | 0.81 | 0.049 | 0.14 |
| 25–OH–D3 LC–MS/MS (ng/mL) | >20 | 18.0 ± 8.37 | 19.7 ± 8.00 | 17.7 ± 6.25 | 21.1 ± 7.40 | 0.52 | 0.13 | 0.57 |
| 25–OH–D2 LC–MS/MS (ng/mL) | >10 | 4.99 ± 2.11 | 4.55 ± 2.74 | 5.86 ± 3.05 | 6.80 ± 7.16 | 0.31 | 0.41 | 0.22 |
n = 52. LDH = Lactate dehydrogenase. HDL = High density lipoprotein. LDL = Low density lipoprotein. PTH = Parathyroid hormone. Ca = Calcium. P = Phosphorous. LC-MS/MS = Liquid chromatography—tandem mass spectrometry. Baseline and follow-up values are expressed as mean ± standard deviation. For intra-group and inter-groups p-value, paired and unpaired t-student test were used respectively. PG = Placebo Group. MG = Magnesium Group.
Figure 3(a) Data distribution of 25-OH-D levels at baseline and follow-up. (b) Vitamin D status in the study population by groups. PG = Placebo Group. MG = Magnesium Group.